CHA
AMGN icon

Cedar Hill Associates’s Amgen AMGN Stock Holding History

Cedar Hill Associates’s Portfolio AMGN Stock Details AMGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-53,585
Closed -$6.34M – 80
2014
Q2 		$6.34M Buy
53,585
+4,020
+8% +$465K 1% 46
2014
Q1 		$6.11M Sell
49,565
-1,386
-3% -$168K 1.03% 47
2013
Q4 		$5.81M Sell
50,951
-3,767
-7% -$429K 1.03% 45
2013
Q3 		$6.12M Sell
54,718
-462
-0.8% -$50.1K 1.17% 43
2013
Q2 		$5.44M Buy
+55,180
New +$5.73M 1.07% 45

Other funds holding AMGN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Cedar Hill Associates's AMGN Position: Q3 2014 in Review

Cedar Hill Associates sold out of Amgen (AMGN) in Q3 2014, closing a stake of 53,585 shares — an estimated $6.34M sold.

Cedar Hill Associates first reported a position in AMGN in Q2 2013 and held it in 5 quarters. The position peaked at $6.34M in Q2 2014. 1,222 funds tracked by Wall St. Rank hold AMGN as of Q3 2014.

  • Cedar Hill Associates reported no remaining Amgen position as of Q3 2014 after selling out during the quarter.
  • Cedar Hill Associates sold 53,585 Amgen shares in Q3 2014, an estimated $6.34M.
  • Cedar Hill Associates first reported a position in Amgen in Q2 2013 and held it in 5 quarters.
  • Cedar Hill Associates's Amgen position peaked at $6.34M in Q2 2014.
  • 1,222 funds tracked by Wall St. Rank held Amgen as of Q3 2014.

Based on Cedar Hill Associates's 13F filing for Q3 2014, filed 12 Nov 2014.